Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.

ABSTRACT:

Objectives

Small cell lung cancer (SCLC) patients of all stages are treated with etoposide and cisplatin or carboplatin with or without surgery or chest radiotherapy. Initial response rates are ≥70% however the majority of patients relapse and are resistant to additional therapies due to pan-resistance to these salvage therapies. Therefore, new treatments are urgently needed. The non-taxane microtubule inhibitor eribulin has produced responses in heavily pretreated breast cancer patients. We evaluated the efficacy of eribulin alone and in combination with radiation in a panel of SCLC cell lines established from patients prior to or after receiving chemotherapy and or radiation.

Material and methods

Growth inhibition by eribulin alone, radiation alone and the combination was

SUBMITTER: Helfrich BA 

PROVIDER: S-EPMC5916851 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature